Business Description
Voyager Therapeutics Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
VT6.GermanyVYGR.MexicoVYGR.USA Description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.54 | |||||
| Equity-to-Asset | 0.44 | |||||
| Debt-to-Equity | 0.3 | |||||
| Debt-to-EBITDA | -1.73 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | -0.44 | |||||
| Beneish M-Score | 0.56 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 61 | |||||
| 3-Year EBITDA Growth Rate | 13.2 | |||||
| 3-Year EPS without NRI Growth Rate | 11.8 | |||||
| 3-Year FCF Growth Rate | -32.5 | |||||
| 3-Year Book Growth Rate | 20.4 | |||||
| Future 3-5Y Total Revenue Growth Rate | -16.95 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.37 | |||||
| 9-Day RSI | 39.65 | |||||
| 14-Day RSI | 48.05 | |||||
| 6-1 Month Momentum % | -14.85 | |||||
| 12-1 Month Momentum % | 100.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.01 | |||||
| Quick Ratio | 2.01 | |||||
| Cash Ratio | 1.8 | |||||
| Days Sales Outstanding | 12.92 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.4 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -29.17 | |||||
| Net Margin % | -24.21 | |||||
| ROE % | -21.43 | |||||
| ROA % | -8.77 | |||||
| ROIC % | -18.43 | |||||
| ROC (Joel Greenblatt) % | -44.07 | |||||
| ROCE % | -16.5 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 4.46 | |||||
| PB Ratio | 3.91 | |||||
| Price-to-Tangible-Book | 3.91 | |||||
| Price-to-Free-Cash-Flow | 31.27 | |||||
| Price-to-Operating-Cash-Flow | 26.3 | |||||
| EV-to-EBIT | -9.96 | |||||
| EV-to-EBITDA | -14.92 | |||||
| EV-to-Forward-EBITDA | -4.27 | |||||
| EV-to-Revenue | 2.9 | |||||
| EV-to-Forward-Revenue | 3.41 | |||||
| EV-to-FCF | 22.7 | |||||
| Price-to-Net-Current-Asset-Value | 7.04 | |||||
| Price-to-Net-Cash | 10.8 | |||||
| Earnings Yield (Greenblatt) % | -10.04 |
